Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy

• DOI: 10.2147/cmar.s160909
• Publication Date: 2018-08-13T17:47:07Z
• Authors: Wei Zhang; Yijun Luo; Xiaoli Wang; Gaohua Han; Peng Wang; Wei Yuan; Sheng-Bin Dai
• Keywords: Chemoradiotherapy

For esophageal cancer patients with a clinical complete response (cCR) after standard-dose radiotherapy concurrent chemotherapy, data on the survival outcomes and recurrence patterns remain scarce. To evaluate impact of dose escalation overall for this subset patients, we carried out current investigation.Medical records 80 cCR chemotherapy at our center from 2010 to 2014 were allocated into group (50.4 Gy, observation group) or radiation dose-escalation (59.4 control group). In cohort study, compared between 2 groups.There no differences in patient characteristics groups. The median recurrence-free times all 38 54 months, respectively. Patients had significantly better 5-year rate (12% vs 0%, p=0.019) (42.8% 21.0%, p=0.028) than group. Additionally, local was higher (p=0.04), ~60% treatment failures even achieving chemoradiotherapy. There significant treatment-related toxicities groups.The results study suggest that those dose-escalated showed control, survival, receiving 50.4 Gy radiotherapy.